Lead Universal CAR-T Candidate
Cancer (unspecified)
Pre-clinicalActive
Key Facts
About Allogenica
Allogenica is pioneering a novel allogeneic (off-the-shelf) cell therapy platform that differentiates stem cells into precursor T cells (pre-T cells) for genetic engineering. The company's approach aims to overcome key limitations of current autologous CAR-T therapies, including complex manufacturing, high costs, and treatment delays. With a lead candidate expected to enter clinical trials in 2026 and recent non-dilutive funding, Allogenica is strengthening its team and technology to position itself as a future leader in accessible cell therapies. The company is privately held and operates at the preclinical development stage.
View full company profileTherapeutic Areas
Other Cancer (unspecified) Drugs
| Drug | Company | Phase |
|---|---|---|
| Allogeneic CAR-NK Platform Product | Simnova Biotherapeutics | Phase 1 |
| CAR-engineered NK cells | Glycostem | Pre-clinical |
| ADU-1805 | Sairopa | Preclinical |
| PSC-derived NK Cells | HebeCell | Pre-clinical |
| mRNA CAR-γδ-T Cell Platform | PhosphoGam | Pre-clinical |
| R-5780 | Rise Therapeutics | Phase 1 |
| Dendritic Cell-Based Cancer Vaccines | Celica Biomedical | Pre-clinical |
| PD-1/VEGF Program | OncoC4 | Not Disclosed |
| FC001 | FerroptoCure | Phase 1 |
| FC004 | FerroptoCure | Preclinical |
| Oncology Drug Delivery | Sporegen | Pre-clinical |